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Background: Infection by 2 or more protozoa is linked with increased severity of disease in marine
mammals with protozoan encephalitis.
Hypothesis/Objectives: To assess whether horses with equine protozoal myeloencephalitis (EPM)
caused by Sarcocystis neurona also have evidence of infection with Neospora hughesi or Toxoplasma
gondii. We hypothesized that horses with EPM would be more likely than horses with cervical ver-
tebral stenotic myelopathy (CVSM) to be positive for antibodies to multiple protozoan parasites.
Animals: One hundred one horses with neurologic disease: 49 with EPM and 52 with CVSM.
Methods: Case review. Archived serum and cerebrospinal fluid (CSF) from 101 horses were exam-
ined. Inclusion criteria included neurologic disease, antemortem or postmortem diagnosis of EPM
or CVSM, and availability of serological results or archived samples for testing. Additional testing
for antibodies was performed on serum for T. gondii, as well as serum and CSF for N. hughesi.
Results: Horses with EPM were more likely than horses with CVSM to have positive immunologic
results for S. neurona on serum (95.9% versus 76.9%, P5 .0058), CSF (98.0% versus 44.2%,
P< .00001), and serum : CSF titer ratio (91.8% versus 0%, P< .00001). Positive results for Neo-
spora and Toxoplasma were uncommon, with total seroprevalence rates of 12.9% and 14.9%,
respectively. The proportions of EPM cases testing positive for Neospora and Toxoplasma (16%
and 12%) were not different from the proportions of CVSM cases testing positive (10% and 17%,
P5 .31 and .47, respectively).
Conclusion: Results do not indicate an important role for protozoal coinfection in EPM in the east-
ern United States.
K E YWORD S
Neospora hughesi, neurology, polyparasitism, Sarcocystis neurona, Toxoplasma gondii
1 | INTRODUCTION
Equine protozoal myeloencephalitis (EPM) is a neurologic disease of
horses caused primarily by Sarcocystis neurona and occasionally by Neo-
spora hughesi. Most horses exposed to these protozoans do not have
Abbreviations: CNS, central nervous system; CSF, cerebrospinal fluid; CVSM,
cervical vertebral stenotic myelopathy; EPM, equine protozoal
myeloencephalitis; IFAT, indirect fluorescent antibody test; NhSAG1, N.
hughesi surface antigen 1; PM, postmortem; SnSAG2, 4/3-S. neurona surface
antigen 2, 4/3.
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clinical disease, but a small percentage develop myeloencephalitis.1–4
Factors that modulate disease progression after infection with
S. neurona are poorly understood, and might include coinfection with
other microorganisms.
Coinfection of 1 host with multiple parasites influences the
immune response of the host as well as the pathogenic severity of the
parasites.5–7 However, studies evaluating parasite coinfections in
humans and animal models are inconsistent in directly correlating coin-
fection with severity of signs.8,9 A recent study found that polyparasi-
tism, specifically looking at coinfections of S. neurona and Toxoplasma
gondii in marine mammals, was associated with increased severity of
signs of neurologic disease and postmortem lesions.10
Neospora hughesi and T. gondii are potential coinfections of proto-
zoal myeloencephalitis in the horse. In contrast to the relatively wide-
spread seroprevalence of S. neurona, seroprevalence of N. hughesi is
much less common, and was recently found in only 2% of potential
EPM cases and 34% of healthy horses tested within the United
States.11,12 Because of the rarity of confirmed N. hughesi cases result-
ing in EPM,13–15 much of the published literature on EPM is focused
on S. neurona.3,4,16,17 Seroprevalence of T. gondii has been examined in
healthy populations of horses worldwide in conjunction with S. neurona
and N. hughesi, and varies from <1% to 34% depending on geographic
location.18–20 A recent study in horses from California found that
horses with signs of neurologic disease compatible with EPM were
more likely to be seropositive to T. gondii compared with non-
neurologic horses.21 To the author’s knowledge, cerebrospinal fluid
(CSF) samples have not been concurrently assessed with serum sam-
ples from horses with neurologic deficits for the presence of antibodies
against these protozoa, nor have horses from the eastern United States
been assessed.
The aim of our study was to assess whether horses previously diag-
nosed with EPM caused by S. neurona also had evidence of infection
with N. hughesi or T. gondii. We hypothesized that horses with EPM
would be more likely than horses with cervical vertebral stenotic myelop-
athy (CVSM) to be positive for antibodies to multiple protozoal parasites.
2 | MATERIALS AND METHODS
2.1 | Case selection
Paired serum and CSF samples from 101 horses were used for our
study. These horses were presented to the George D. Widener Hospi-
tal for Large Animals at New Bolton Center for neurologic evaluation
over a 6-year period (March 2010 to November 2016). Serum and CSF
samples were initially collected for diagnostic purposes, including S.
neurona and occasionally N. hughesi immunologic analysis. After sample
collection and initial testing the remaining serum and CSF samples
were stored at2808C until analysis for our study.
Cases were categorized as EPM or CVSM. Each category was sub-
divided into confirmed cases and presumptive cases depending on
whether postmortem confirmation of diagnosis was available. Con-
firmed EPM cases had clinical history, neurologic deficits, and postmor-
tem lesions consistent with EPM. The pathologic criteria included
multifocal or focally extensive lymphocytic, lymphohistiocytic, or lym-
phoplasmacytic myelitis, encephalitis, or both. Occasionally, additional
confirmatory tests such as immunohistochemistry or PCR tests for S.
neurona were used at the discretion of the university pathologists. Pre-
sumptive EPM cases had clinical history and neurologic deficits consist-
ent with EPM, exclusion of other likely diseases by appropriate
diagnostic testing, and SnSAG2, 4/3 ELISA serum : CSF titer ratios
50. Confirmed CVSM cases had clinical history, neurologic deficits,
and postmortem lesions consistent with CVSM. The pathologic criteria
included axonal degeneration and demyelination consistent with spinal
cord compression. Nineteen out of 23 (83%) of these cases also had
myelographic studies consistent with spinal cord compression, and all
had SnSAG2, 4/3 ELISA serum : CSF titer ratios 100 with a normal
specific index. Presumptive CVSM cases had histories and neurologic
deficits consistent with CVSM, myelographic studies indicative of spinal
cord compression at 1 or more sites, and SnSAG2, 4/3 ELISA
serum : CSF titer ratios 100 with a normal specific index.
Although necropsies were not performed in all cases, horses were
excluded from the study if the necropsy findings did not support the
antemortem diagnosis. Horses were also excluded if inadequate sample
volumes were available to perform all immunologic tests.
2.2 | Antibody testing
Testing for antibodies against S. neurona (SnSAG 2, 4/3 ELISA; SnSAG
2, 4/3, and NhSAG1 ELISA were performed at Equine Diagnostic Solu-
tions, Lexington, Kentucky) was performed at the time of initial collec-
tion for obtainment of a clinical diagnosis, and results were collected
from medical records. Nineteen cases were also tested for antibodies
against N. hughesi (NhSAG1 ELISA) as part of the initial neurologic eval-
uation; this additional testing was performed at the attending clinician’s
discretion.
All samples were submitted for testing for antibodies against N.
hughesi (NhSAG1 ELISA; SnSAG 2, 4/3, and NhSAG1 ELISA were per-
formed at Equine Diagnostic Solutions) if not previously performed.14
All samples were submitted for detection of antibodies against T. gondii
via western blot (Western blot analysis was performed at M.H. Gluck
Equine Research Center, University of Kentucky, Lexington,
Kentucky).22–26 Samples were considered positive for T. gondii if there
was evidence of antibody reactivity to the immunodominant major
tachyzoite surface antigen SAG1.
2.3 | Statistical analysis
Immunologic results were dichotomized as positive or negative for anti-
bodies against each protozoan. The proportions of positive horses in
each group were compared using the “N-1” Chi-squared test.27,28 A P
value of< .05 was used to determine statistical significance.
3 | RESULTS
A total of 101 horses were included in the study. Two cases of the
original 103 were excluded from analysis because 1 case did not have
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T. gondii results recorded, and the other case was positive for both
EPM and CVSM.
Forty-nine cases were categorized as EPM, with 29 considered
presumptive and 20 confirmed on postmortem examination. One of
the EPM cases in this group was diagnosed with N. hughesi infection
on the basis of immunologic testing and postmortem examination, and
the remaining 48 cases were diagnosed with S. neurona infection. Fifty-
two cases were categorized as CVSM, with 29 considered presumptive
and 23 confirmed on post-mortem examination.
As anticipated, the vast majority (>90%) of EPM cases were posi-
tive for S. neurona on serum, CSF, and serum : CSF titer ratio (Table 1).
Serum titers were variable, with a range from negative (<1 : 250) to
1 : 4000 (median titer 1 : 500). The majority of CVSM cases (76.9%)
were also positive for S. neurona on serum, though less than half were
positive on CSF and none on serum : CSF titer ratio. Serum titers for
the CVSM cases were also variable, with a range from negative
(<1 : 250) to 1 : 4000 (median titer 1 : 500). Equine protozoal myeloen-
cephalitis cases were significantly more likely than CVSM cases to be
positive for S. neurona on serum (P5 .0058), CSF (P< .00001), and
serum : CSF titer ratio (P< .00001).
Overall, 12.9% of all cases were positive on serum for N. hughesi.
The proportion of EPM cases that tested positive did not differ from
the proportion of CVSM cases (P5 .31). Only 1 EPM case showed evi-
dence of intrathecal antibody production with a positive serum : CSF
titer ratio, and this case was confirmed to have N. hughesi rather than
S. neurona on necropsy and did not have a positive titer ratio for S. neu-
rona. None of the CVSM cases had positive CSF or titer ratio results
for N. hughesi.
Overall, 14.9% of all cases were weakly or very weakly positive on
serum for T. gondii. No horse in either group had a serum result consid-
ered positive or strongly positive. The proportion of EPM cases that
tested weakly positive for T. gondii did not differ from the proportion
of CVSM cases (P5 .47). Toxoplasma gondii testing was not performed
on CSF samples because of the lack of positive serum results.
4 | DISCUSSION
Our study investigated the prevalence of T. gondii and N. hughesi infec-
tion in conjunction with either EPM or CVSM in horses from the east-
ern United States. Because antigen detection techniques for these
protozoans are generally unavailable or unreliable in clinical cases, anti-
body tests were used to detect infection. Subclinical infection (expo-
sure) was inferred for horses with positive serum but negative titer
ratio results. Clinical infection was assumed for horses that had positive
serum : CSF titer ratios and also met the other criteria for EPM diagno-
sis. Over the 6-year interval studied, no horse was diagnosed with clini-
cal coinfection (ie, positive titer ratio to more than 1 protozoa).
Similarly, occurrence of subclinical coinfection with these protozoa was
found to be negligible in both groups of horses. Therefore, our data do
not support protozoal coinfection as a common finding in horses with
neurologic disease from the eastern United States, suggesting that
coinfection with protozoan species is unlikely to play an important role
in development of clinical disease caused by S. neurona infection.
Studies assessing seroprevalence of S. neurona and N. hughesi in
horses in the United States have found variable results in different pop-
ulations. Seroprevalence of antibodies against S. neurona and N. hughesi
in 5250 healthy horses across the United States was 78% and 34%,
respectively.11 Seroprevalence of S. neurona and N. hughesi in 3123
horses across the United States with clinical signs compatible with
EPM was 27.8% and 2.0%, respectively.12 Our study population came
from a region with high exposure to S. neurona, as shown by the 77%
seroprevalence in the CVSM group. However, exposure to N. hughesi
was much less common, with 12.9% of all cases having detectable anti-
body concentrations.
Toxoplasma gondii is rarely linked to clinical disease in the horse,
although it was originally implicated as the causative agent of “segmen-
tal myelitis” (now EPM) before S. neurona was identified as a distinct
protozoan species. Cases of ophthalmic and transplacental infections
caused by T. gondii occur in horses, but horses appear to be relatively
TABLE 1 Antibody test results
All EPMa
(n549) n (%)
All CVSMa
(n552) n (%) P valuea
PM EPMb
(n520) n (%)
PM CVSMb
(n523) n (%) P valueb
S. neurona
1Serum 47 (96%) 40 (77%) .0058 18 (90%) 16 (70%) .10
1CSF 48 (98%) 23 (44%) <.00001 19 (95%) 10 (44%) .00030
1Ratio 45 (92%) 0 (0%) <.00001 16 (80%) 0 (0%) <.00001
N. hughesi
1Serum 8 (16%) 5 (10%) .31 5 (25%) 3 (13%) .31
1CSF 2 (4%) 0 (0%) .14 2 (10%) 0 (0%) .12
1Ratio 1 (2%) 0 (0%) .30 1 (5%) 0 (0%) .28
T. gondii
1Serumc 6 (12%) 9 (17%) .47 3 (15%) 7 (30%) .23
aColumns display data for all EPM and CVSM cases (confirmed1 presumptive) and relevant statistical analyses.
bColumns display data only for EPM and CVSM cases that were confirmed on postmortem evaluation, with relevant statistical analyses.
cPositive serum results for T. gondii were only weak or very weak positives; no strong positive results were obtained.
Abbreviations: EPM, equine protozoal myeloencephalitis; PM, postmortem; CVSM, cervical vertebral stenotic myelopathy; 1, positive test result; CSF,
cerebrospinal fluid; ratio, serum : CSF titer ratio.
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resistant to clinical disease from T. gondii compared with most warm-
blooded vertebrates.29,30 Recently, horses with neurologic disease in
California had >6 times odds of being seropositive to T. gondii com-
pared with controls (using a titer cutoff of 1 : 320).21 However, that
study did not assess CSF antibody concentrations, serum : CSF titer
ratios, or have necropsy confirmation of diagnosis. Therefore, the
authors could not assess whether coinfections contributed to develop-
ment or severity of EPM. Protozoal coinfections, specifically concurrent
infections with S. neurona and T. gondii, are an important cause of
encephalitis in marine life.10 Marine species could be particularly sensi-
tive to protozoal infections, or have increased exposure based on geo-
graphic location and contaminated waterways.
Not all cases used for our study had postmortem confirmation of
diagnosis. The EPM group was diagnosed using serum : CSF titer ratios
or necropsy findings, and the CVSM group diagnosed with myelogra-
phy or necropsy in addition to negative serum : CSF titer ratios for
EPM. The CVSM group established a convenient negative control
group from a CSF sampling perspective, because horses undergoing
myelography at the George D. Widener Hospital for Large Animals at
New Bolton Center routinely have CSF and serum samples collected
and stored. As this was a retrospective study from banked samples on
client-owned horses, results of postmortem evaluation were not always
available. While postmortem examination is the gold standard for diag-
nosis of protozoal infections and CVSM, cases without this diagnostic
were included in our study to incorporate a larger sample size. Because
stringent criteria were used for inclusion in the study, we have high
confidence in the validity of the cases.
When postmortem examination was performed, organism, or anti-
gen detection techniques such as immunohistochemistry and PCR
were not always used. Protozoal organisms can be difficult to identify
in clinical cases, which frequently have been treated extensively with
antiprotozoal agents before death, thus substantially decreasing the
protozoal load. Therefore, the possibility exists that horses with coin-
fections were missed, because we relied heavily on immunological test
results (specifically the serum : CSF titer ratio) to determine cause of
infection. However, because of high sensitivity and specificity of the
SnSAG2, 4/3 ELISA,3 as well as the absence of immunological evidence
for N. hughesi or T. gondii infection, we believe that clinical coinfections
were not present in this population. Future work should include a
larger population of horses from additional geographical regions.
Diagnostic tests for T. gondii have not been validated for use with
horse samples.31 Therefore, Western blot was used to detect antibod-
ies against T. gondii, which is consistent with prior studies investigating
T. gondii infection in several other species, including humans, ruminants,
and mice.22–26 Western blot is not a quantitative test, which prevents
its use for establishing an end-point titer. However, it is an excellent
qualitative assay that provides a visual confirmation of the expected
antibody reactivity with known immunodominant antigens, thereby giv-
ing high confidence in a positive versus negative result. In our study,
cases tested “weakly positive,” “very weakly positive,” or “negative” on
serum, which was deemed clinically insignificant; for this reason, addi-
tional testing of CSF was not pursued.
In conclusion, coinfections with either T. gondii or N. hughesi did
not appear to contribute to development of clinical EPM caused by S.
neurona infections in horses in the eastern United States. The absence
of clinically relevant coinfections might be region-specific and related
to low equine exposure to protozoa other than S. neurona. Other infec-
tious agents, including viruses and bacteria, could also play a role in the
development of clinical EPM through either direct effects or immune
modulation. Regardless, further work is needed to elucidate the com-
plexities of clinical EPM for the development of additional preventative
and treatment strategies.
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